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Advancing the repurposing of ivermectin for malaria
There is ever-increasing anticipation for the potential of 
mass drug administration of endectocides (also known 
as systemic insecticides) to reduce malaria transmission, 
with ivermectin emerging as the most likely first-in-class 
endectocide.1 More than half of the 46 papers published 
on this subject in the past decade appeared in the past 
2 years. 23 projects are registered in the MESA Track 
database, of which seven are active today; and, more 
importantly, trial mapping by the Malaria Ivermectin 
Roadmap2 shows that abundant new evidence on the 
topic will be available by 2020.
Why is there so much interest in repurposing 
ivermectin? After achieving remarkable advances from 
2000 to 2015, the global fight against malaria has stalled.3 
Beyond funding and access gaps, residual transmission—
driven by mosquito behavioural adaptations that allow 
avoidance of home-based insecticides—has become a key 
liability for vector control, and challenges achievement of 
the global goals set forth by WHO.4
Ivermectin lays the path for a whole new concept: 
drug-based vector control.5,6 Ivermectin, or indeed any 
effective endectocide, could be administered to eligible 
members of the at-risk community as a complementary 
tool for vector control. It could be administered alone 
or in combination with partner drugs to allow for 
integrated management of malaria or neglected tropical 
diseases, directly responding to residual transmission by 
targeting malaria and some lymphatic filariasis vectors, 
regardless of their feeding behaviour. 7,8
In The Lancet, Brian Foy and colleagues9 report 
the results of the RIMDAMAL trial, which enrolled 
participants from eight village clusters in a high-
transmission area in southwestern Burkina Faso. Eligible 
village residents in the control and intervention groups 
received a single 150–200 μg/kg dose of ivermectin plus 
400 mg of albendazole, but those in the intervention 
group received five additional 3-weekly doses of 
ivermectin alone, with mass drug administration 
coverage of 70–75% across the 18-week intervention 
period. The active case detection cohort comprised 
children aged 5 years or younger who were living in 
these villages. These children were visited three times 
every 2 weeks by a nurse who tested them for malaria, 
assessed symptoms, and provided treatment, if needed, 
allowing for monitoring of malaria incidence in this 
key age group. The primary outcome was cumulative 
malaria incidence (adjusted for sex and clustering), 
which was reduced in the intervention group 
(648 episodes among 327 children; 2·00 episodes per 
child) compared with the control group (647 episodes 
among 263 children; 2·49 episodes per child; risk 
ratio 0·81 [95% CI 0·72–0·90]; risk difference –0·49 
[–0·79 to –0·21], p=0·0009).
Although the sample size was small and the regimen 
chosen for this trial (six doses over an 18-week period) 
might not have been optimal for implementation, these 
results provide the first evidence of an effect of mass 
ivermectin administration that goes beyond mosquito 
mortality, showing a measurable reduction in malaria 
incidence in children aged 5 years or younger, thereby 
demonstrating the concept of community effects. 
This trial continues to build the evidence base and, 
thus, increase interest in the repurposing of an existing 
drug that could help bridge to a more effective malaria 
strategy at a time when malaria progress is threatened, 
as shown by the increase in cases globally.
Ongoing or soon-to-start trials will assess the 
efficacy and safety of the new malaria indication 
of ivermectin with two different dosing regimens: 
either three consecutive daily doses of 300 μg/kg, as 
identified by the IVERMAL dose-ranging study,10 which 
showed a good compromise between safety and the 
effects on mosquitoes; or a single-dose regimen of 
400 μg/kg, currently used for control of lymphatic 
filariasis. Pharmacokinetic and modelling data support 
the evaluation of both regimens for the malaria 
indication. Ivermectin will be tested either alone or in 
combination with other drug-based strategies against 
malaria, delivered as seasonal malaria chemoprophylaxis 
or community mass drug administration.
Beyond the generation of evidence regarding safety 
and efficacy of ivermectin, the crucial next steps are 
determination of the best distribution approaches, 
identification of synergies in alliance with neglected 
tropical disease programmes, and ensuring a supply of 
the drug for campaigns at an affordable cost. Interested 
manufacturers must ultimately have their products 
prequalified by WHO to allow for the use of multilateral 
funds in the procurement process. The new malaria 
indication of ivermectin, combined with appropriate 
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demand forecasting, could incentivise investment by 
manufacturers of generics.
Foy and colleagues’ work9 is an important step for 
a promising, preventive intervention for malaria. 
The development of this new tool will require clear 
epidemiological (ie, human disease) impact and 
coordination with the neglected tropical diseases 
community,11 but the ultimate results could help us to 
get back on track to meet the global malaria goals.
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